New Drug Combination for Advanced Skin Lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a chemotherapy combination (aclarubicin plus three other drugs) in patients 60 and older whose cutaneous T-cell lymphoma (a blood cancer affecting the skin) did not respond to previous treatments. The goal is to see if this new combination works better and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 60 years old
- You have cutaneous T-cell lymphoma or Sézary syndrome confirmed by a skin biopsy
- Your lymphoma is stage II-B, III, or IV (moderate to advanced)
- You have received at least one previous cancer treatment that didn't fully work
- Your blood counts, liver, and kidney function are adequate (checked by blood tests)
- Any side effects from prior cancer treatments have mostly cleared up
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called DT-7012 for people with a type of skin lymphoma (mycosis fungoides or Sezary syndrome) that has come back or not responded to at least two prior treatments. The goal is to find a safe dose and see if it shrinks the lymphoma.
This trial tests two medications (golidocitinib and chidamide) for people with a type of lymphoma that affects the skin. The combo may help control the disease when other treatments haven't worked or have stopped working.
This trial tests a chemotherapy combination called CAOP (four drugs given together) for patients 65 and older with a type of lymphoma called peripheral T-cell lymphoma who have never received cancer treatment before. The goal is to see if this combination works well and is safe for older adults.
This study tests a combination of three drugs (azacitidine, chidamide, and a PD-1 inhibitor) for T-cell lymphomas that have returned or stopped responding to previous treatment. The goal is to see if this combination can help shrink the cancer.
This trial tests a new combination of drugs (teniposide, a PD-1 checkpoint inhibitor, and selinexor) for people with relapsed or refractory primary central nervous system lymphoma. It aims to see if this three-drug approach can shrink tumors or slow the disease when previous treatments haven't worked.
This study tests whether a new three-drug combination (Pola-ZR-Glo) works safely and effectively for older adults with a type of blood cancer called large B-cell lymphoma who cannot or prefer not to receive standard chemotherapy. The goal is to find a gentler treatment option for frail or elderly patients.
Hear when a new Sezary Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.